Dynamic Contrast-Enhanced MRI Protocol for Liver Imaging
For optimal liver lesion characterization, perform dual-phase dynamic MRI with late arterial phase acquisition at 10-15 seconds and portal venous phase at 50 seconds or later after contrast arrival in the abdominal aorta. 1
Technical Protocol Overview
Pre-Contrast Preparation
- Use test bolus imaging to determine aortic transit time before the diagnostic contrast injection 2, 3
- This individualized timing approach reduces time-variability among patients by approximately 62% compared to fixed timing protocols 4
Phase 1: Late Arterial Phase (Hepatic Arterial Phase)
Timing specifications:
- Acquire images with k-space center at 10-15 seconds after contrast material arrives in the abdominal aorta 2
- For hypervascular hepatocellular carcinoma specifically, optimal timing is 9-12 seconds after aortic contrast arrival 3
- The late arterial phase is preferred over early arterial phase because maximal lesion enhancement occurs more frequently during this window 1
Key technical points:
- This phase captures intense lesion enhancement with minimal background parenchymal enhancement 3
- At this timing, the liver enhances approximately 29% of its maximal enhancement (which occurs during portal venous phase) 5
- Intense splenic enhancement with moiré pattern without intense hepatic enhancement characteristically occurs at 10-15 seconds 2
Phase 2: Portal Venous Phase
Timing specifications:
- Acquire images at 50 seconds or later after contrast arrival in the abdominal aorta 2
- Alternative timing: 49-60 seconds range is acceptable 2, 3
- For hepatobiliary agents (gadoxetate), consider later acquisition after 70 seconds to improve detection of washout and enhancing capsule 6
Key technical points:
- Aortic and splenic enhancement significantly decrease from 45 to 50 seconds, making this optimal for portal venous imaging 2
- Hepatic parenchyma and hepatic veins reach peak enhancement during this phase 7
- Spleen-to-liver contrast-to-noise ratio begins decreasing at 20 seconds and continues to decline, supporting the 50+ second timing 2
Practical Implementation
Empirical Timing Without Test Bolus
If test bolus imaging is not performed, use empirical delays of 28-34 seconds for arterial phase and 68 seconds or later for portal venous phase after initiating contrast injection 2
Real-Time Bolus Tracking Alternative
- Real-time bolus-triggered technique captures the targeted arterial phase in 94% of cases compared to 73% with fixed timing 4
- This represents an expected improvement in timing accuracy in 28% of patients 4
- Mean bolus transit time to peak lesion contrast is 8.1 ± 2.7 seconds following arterial detection 4
Contrast Agent Considerations
Extracellular Gadolinium Agents
- Standard agents (gadopentetate dimeglumine) are commonly used for dynamic phases 1
- Follow the dual-phase timing protocol as outlined above 2, 3
Hepatobiliary Agents
- Gadoxetate disodium (Gd-EOB-DTPA): Hepatobiliary phase occurs at approximately 20 minutes post-injection 1
- Gadobenate dimeglumine (Gd-BOPTA): Hepatobiliary phase occurs at 60-120 minutes post-injection 6
- For gadoxetate, consider using arterial subtraction images to overcome weak arterial phase hyperenhancement and increase APHE detection from 80.6% to 91.9% 6
Common Pitfalls to Avoid
- Avoid early arterial phase timing (5 seconds): This is too early and misses optimal lesion enhancement 2
- Avoid portal venous phase before 50 seconds: Enhancement patterns are suboptimal before this time 2
- Don't use fixed timing for all patients: Individual variation in contrast arrival time is significant; test bolus or real-time triggering improves accuracy 4
- Watch for motion artifacts: Ensure adequate breath-hold technique; motion artifacts occur in approximately 3% of patients 7